Oncotelic Therapeutics Opens Access to AI Platform for Biomedical Research

Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced it has opened research access to PDAOAI, its proprietary evidence interrogation platform designed to extract biologically meaningful signals from large and complex biomedical datasets without training bespoke large language models on proprietary data. The company is also providing researchers access to a comprehensive TGF beta literature corpus comprising more than 125,000 PubMed abstracts through a dedicated Discord research channel, with the platform developed alongside Oncotelic's clinical and preclinical programs to enhance the speed, depth, and efficiency of discovery across its pipeline.

The platform's development aligns with Oncotelic's broader strategy to leverage artificial intelligence in biotechnology, following its acquisition of PointR Data Inc. in November 2019 to build an AI-driven biotechnology company. This move represents a significant step in making advanced analytical tools available to the research community, potentially accelerating discoveries in oncology and other therapeutic areas. The company's focus includes rare pediatric cancers, with rare pediatric designation for Diffuse Intrinsic Pontine Glioma through OT-101 via its 45% joint venture GMP Bio, as well as programs targeting melanoma and Acute Myeloid Leukemia.

Beyond oncology, Oncotelic has expanded its portfolio through the acquisition of AL-101 during the fourth quarter of 2021, intended for intranasal delivery of apomorphine targeting Parkinson Disease, erectile dysfunction, female sexual disorder, and hypoactive sexual desire disorder. The company detailed this development in its 2024 Annual Report on form 10-K filed with the SEC on April 15, 2025, available through standard regulatory channels. The opening of the PDAOAI platform to researchers represents a strategic initiative to foster collaboration and innovation in biomedical research, potentially leading to more efficient drug development processes and improved treatment outcomes for patients across multiple disease areas.

The implications of this announcement extend beyond immediate research applications, potentially setting a precedent for how biotechnology companies leverage artificial intelligence while addressing data privacy concerns through approaches that don't require training on proprietary datasets. By providing access to both the analytical platform and a substantial literature corpus, Oncotelic is creating infrastructure that could accelerate hypothesis generation and validation across the biomedical research community. This development occurs within a broader context of increasing integration of artificial intelligence in life sciences, where tools like PDAOAI could help researchers navigate the growing volume of biomedical data more effectively.